2021/07/01
论文
论文标题：Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
作者：Dami A. Collier, Isabella A. T. M. Ferreira, Prasanti Kotagiri, Rawlings Datir, Eleanor Lim, Emma Touizer, Bo Meng, Adam Abdullahi, Anne Elmer, Nathalie Kingston, Barbara Graves, Emma Le Gresley, Daniela Caputo, Laura Bergamaschi, Kenneth G. C. Smith, John R. Bradley, Lourdes Ceron-Gutierrez, Paulina Cortes-Acevedo, Gabriela Barcenas-Morales, Michelle A. Linterman, Laura McCoy, Chris Davis, Emma Thomson, Paul A. Lyons, Eoin McKinney, Rainer Doffinger, Mark Wills, Ravindra K. Gupta
期刊：Nature
发表时间：2021/06/30
数字识别码：10.1038/s41586-021-03739-1
摘要：Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, data are scarce on vaccine efficacy against variants of concern (VOC) in individuals above 80 years of age1. Here we analysed immune responses following vaccination with mRNA vaccine BNT162b22 in elderly participants and younger health care workers. Serum neutralisation and binding IgG/IgA after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old. Sera from participants above 80 showed significantly lower neutralisation potency against B.1.1.7, B.1.351 and P.1. variants of concern as compared to wild type and were more likely to lack any neutralisation against VOC following the first dose. However, following the second dose, neutralisation against VOC was detectable regardless of age. Frequency of SARS-CoV-2 Spike specific B-memory cells was higher in elderly responders versus non-responders after first dose. Elderly participants demonstrated clear reduction in somatic hypermutation of class switched cells. SARS-CoV-2 Spike specific T- cell IFNγ and IL-2 responses decreased with increasing age, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high risk population that warrant specific measures to boost vaccine responses, particularly where variants of concern are circulating.
